Ballentine Partners, LLC Geron Corp Transaction History
Ballentine Partners, LLC
- $7.1 Billion
- Q3 2025
A detailed history of Ballentine Partners, LLC transactions in Geron Corp stock. As of the latest transaction made, Ballentine Partners, LLC holds 93,971 shares of GERN stock, worth $105,247. This represents 0.0% of its overall portfolio holdings.
Number of Shares
93,971
Previous 82,084
14.48%
Holding current value
$105,247
Previous $115,000
11.3%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding GERN
# of Institutions
288Shares Held
502MCall Options Held
643KPut Options Held
276K-
Ra Capital Management, L.P. Boston, MA60.4MShares$67.6 Million1.42% of portfolio
-
Black Rock Inc. New York, NY46.6MShares$52.1 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT41.1MShares$46 Million1.78% of portfolio
-
Vanguard Group Inc Valley Forge, PA34.4MShares$38.6 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA27.2MShares$30.5 Million5.93% of portfolio
About GERON CORP
- Ticker GERN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 377,819,008
- Market Cap $423M
- Description
- Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...